tec in 6

Tec-IN-6 is an inhibitor of Tec kinase, it also blocks unconventional secretion of fibroblast growth factor 2 (FGF2).

BTK-IN-6 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with research potential in immune diseases, cardiovascular diseases, cancer, viral infections, inflammation, metabolic endocrine dysfunction, and neurological disorders (for more information).

N-[5-[[[3-(6-Amino-4-methylpyridin-3-yl)-1-methyl-1H-indazol-5-yl]carbonyl]amino]-2-methylphenyl]-N′-methylterephthalamide had an IC50 value of 22 nM in a BD2 DEC-Tec assay.

N-[5-[[[3-(6-Amino-2-methylpyridin-3-yl)-1-methyl-1H-indazol-5-yl]carbonyl]amino]-2-methylphenyl]-N′-methylterephthalamide had an IC50 value of 94 nM in a BD2 DEC-Tec assay.

Acalabrutinib-d4 is a deuterated compound of Acalabrutinib. Acalabrutinib has a CAS number of 1420477-60-6. Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.